Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

We evaluated progression-free survival (PFS) rate of patients treated with lenalidomide/dexamethasone (Len/Dex), the efficacy of the combination, and the prognostic significance of treatment at biochemical vs. clinical relapse on PFS in 207 consecutive myeloma patients treated with Len/Dex in second...

Descripción completa

Detalles Bibliográficos
Autores principales: Katodritou, Eirini, Kyrtsonis, Marie-Christine, Delimpasi, Sosana, Kyriakou, Despoina, Symeonidis, Argiris, Spanoudakis, Emmanouil, Vasilopoulos, Georgios, Anagnostopoulos, Achilles, Kioumi, Anna, Zikos, Panagiotis, Aktypi, Anthi, Briasoulis, Evangelos, Megalakaki, Aikaterini, Repousis, Panayiotis, Adamopoulos, Ioannis, Gogos, Dimitrios, Kotsopoulou, Maria, Pappa, Vassiliki, Papadaki, Eleni, Fotiou, Despoina, Nikolaou, Eftychia, Giannopoulou, Evlambia, Hatzimichael, Eleftheria, Giannakoulas, Nikolaos, Douka, Vassiliki, Kokoviadou, Kyriaki, Timotheatou, Despoina, Terpos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097756/
https://www.ncbi.nlm.nih.gov/pubmed/29756171
http://dx.doi.org/10.1007/s00277-018-3361-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097756/
https://www.ncbi.nlm.nih.gov/pubmed/29756171
http://dx.doi.org/10.1007/s00277-018-3361-2

Ejemplares similares